NO20020391L - 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater - Google Patents

8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater

Info

Publication number
NO20020391L
NO20020391L NO20020391A NO20020391A NO20020391L NO 20020391 L NO20020391 L NO 20020391L NO 20020391 A NO20020391 A NO 20020391A NO 20020391 A NO20020391 A NO 20020391A NO 20020391 L NO20020391 L NO 20020391L
Authority
NO
Norway
Prior art keywords
purin
triazolo
dihydro
phenyl
derivatives
Prior art date
Application number
NO20020391A
Other languages
English (en)
Other versions
NO20020391D0 (no
Inventor
Jordi Gracia Ferrer
Joan Feixas Gras
Jose Manuel Prieto Soto
Armando Vega Noverola
Bernat Vidal Juan
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of NO20020391D0 publication Critical patent/NO20020391D0/no
Publication of NO20020391L publication Critical patent/NO20020391L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

8-fenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-on-deri-vater med formel (I):. eller et farmasøytisk akseptabelt salt derav;. fremgangsmåter ved deres fremstilling, farmasøytiske sam-mensetninger inneholdende dem og deres anvendelse som PDE 5-inhibitorer.
NO20020391A 1999-07-27 2002-01-25 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater NO20020391L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
PCT/EP2000/007062 WO2001007441A1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES

Publications (2)

Publication Number Publication Date
NO20020391D0 NO20020391D0 (no) 2002-01-25
NO20020391L true NO20020391L (no) 2002-03-25

Family

ID=8309393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020391A NO20020391L (no) 1999-07-27 2002-01-25 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater

Country Status (34)

Country Link
US (1) US7034016B2 (no)
EP (1) EP1198464B1 (no)
JP (1) JP2003505461A (no)
KR (1) KR20020022786A (no)
CN (1) CN1198825C (no)
AR (1) AR024969A1 (no)
AT (1) ATE251625T1 (no)
AU (1) AU777571B2 (no)
BG (1) BG106346A (no)
BR (1) BR0012764A (no)
CA (1) CA2380181A1 (no)
CO (1) CO5190717A1 (no)
CZ (1) CZ2002311A3 (no)
DE (1) DE60005838T2 (no)
DK (1) DK1198464T3 (no)
EE (1) EE200200046A (no)
ES (2) ES2166270B1 (no)
HK (1) HK1044332B (no)
HU (1) HUP0202103A3 (no)
IL (1) IL147770A0 (no)
MY (1) MY129590A (no)
NO (1) NO20020391L (no)
NZ (1) NZ516780A (no)
PE (1) PE20010401A1 (no)
PL (1) PL353827A1 (no)
PT (1) PT1198464E (no)
RU (1) RU2258705C2 (no)
SK (1) SK1352002A3 (no)
TR (1) TR200200785T2 (no)
TW (1) TW568912B (no)
UA (1) UA73513C2 (no)
UY (1) UY26258A1 (no)
WO (1) WO2001007441A1 (no)
ZA (1) ZA200200561B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE0300917D0 (sv) 2003-03-31 2003-03-31 St Jude Medical Multi-chamber pacing system
JP2007501866A (ja) * 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008520679A (ja) * 2004-11-18 2008-06-19 シェーリング コーポレイション うっ血性心不全の処置のためにｐｄｅｖインヒビターを使用する方法
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
IL275817B2 (en) * 2018-01-04 2024-04-01 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof
US20210347778A1 (en) * 2018-08-30 2021-11-11 Tera Stone Co., Ltd Hydrazinopurine compound and triazolopurine compound for inhibiting xanthine oxidase
CN112225761B (zh) * 2020-12-16 2021-03-12 南京颐媛生物医学研究院有限公司 一种嘧啶并三氮唑及其合成方法
CN116964055A (zh) * 2021-03-09 2023-10-27 巴斯夫欧洲公司 杀害虫的三环化合物
BR112023018040A2 (pt) * 2021-03-09 2023-10-03 Basf Se Compostos, uso dos compostos, mistura pesticida, composições agroquímicas ou veterinárias, métodos para controlar pragas invertebradas e semente

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
DE3347290A1 (de) 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DK0417790T3 (da) * 1989-09-14 1997-04-07 Kyowa Hakko Kogyo Kk S-triazolo(3,4-i)purin-derivater
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
US5990118A (en) * 1995-02-21 1999-11-23 Yamasa Corporation Purine compounds and xanthine oxidase inhibitors
US6723719B1 (en) * 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
AU4501199A (en) * 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US7060824B2 (en) * 2000-08-09 2006-06-13 Almirall Prodesfarma, S.A. Pyrrolotriazolopyrimidinone derivatives

Also Published As

Publication number Publication date
ES2208378T3 (es) 2004-06-16
TW568912B (en) 2004-01-01
DE60005838T2 (de) 2004-08-19
ZA200200561B (en) 2003-06-25
HK1044332B (en) 2004-10-15
CN1198825C (zh) 2005-04-27
EP1198464B1 (en) 2003-10-08
ES2166270B1 (es) 2003-04-01
US20030060627A1 (en) 2003-03-27
CO5190717A1 (es) 2002-08-29
CZ2002311A3 (cs) 2003-01-15
CN1374962A (zh) 2002-10-16
AU6277200A (en) 2001-02-13
HK1044332A1 (en) 2002-10-18
TR200200785T2 (tr) 2002-09-23
US7034016B2 (en) 2006-04-25
BR0012764A (pt) 2002-07-02
ATE251625T1 (de) 2003-10-15
RU2258705C2 (ru) 2005-08-20
AU777571B2 (en) 2004-10-21
AR024969A1 (es) 2002-10-30
JP2003505461A (ja) 2003-02-12
IL147770A0 (en) 2002-08-14
DK1198464T3 (da) 2004-02-16
SK1352002A3 (en) 2003-04-01
MY129590A (en) 2007-04-30
HUP0202103A2 (en) 2002-10-28
UA73513C2 (en) 2005-08-15
ES2166270A1 (es) 2002-04-01
CA2380181A1 (en) 2001-02-01
NO20020391D0 (no) 2002-01-25
EP1198464A1 (en) 2002-04-24
PE20010401A1 (es) 2001-04-16
PL353827A1 (en) 2003-12-01
NZ516780A (en) 2004-01-30
KR20020022786A (ko) 2002-03-27
HUP0202103A3 (en) 2004-12-28
WO2001007441A1 (en) 2001-02-01
UY26258A1 (es) 2000-12-29
DE60005838D1 (de) 2003-11-13
BG106346A (en) 2002-09-30
PT1198464E (pt) 2004-02-27
EE200200046A (et) 2003-04-15

Similar Documents

Publication Publication Date Title
NO20020391L (no) 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater
HUP0300565A3 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
NO992524L (no) Konsenserte bicykliske pyrimidin-derivater
MY132642A (en) Naphthyridine derivatives
NO20014102L (no) Nye tricykliske forbindelser og deres anvendelse innenfor medisin, fremgangsmåte for deres fremstilling og farmasöytisksammensetning som inneholder dem
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
MXPA03010877A (es) Derivados de 2-anilin-pirimida como inhibidores de cinasa dependientes de ciclina.
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
IL144096A0 (en) Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
HK1046527A1 (zh) 金剛烷衍生物
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
ECSP045378A (es) Derivados novedosos de diazabiciclononeno
NO20070570L (no) Forbindelser.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
WO2002048148A3 (en) Pyrazolopyridine derivatives
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20004089L (no) Nye triazolo(4,5-d)pyrimidinforbindelser
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
EA200000355A2 (ru) Промышленные изделия
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
NO20054974L (no) 9-azabicyklo(3.3.1)non-6-en derivater med et heteroatom i 3-posisjonen som renin inhibitorer
NO20063768L (no) 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer